Skip to main content
| News

Straumann plans to build innovation center in the Basel Area

29.10.2021

The Basel-based dental specialist Straumann is planning to construct a new technology and innovation center in Arlesheim in the canton of Basel-Landschaft. This should lead to the creation of 240 new jobs. Moreover, Straumann has acquired a stake in the medtech startup Mininavident, which is also based in the Basel Area.

Straumann's headquarters in Basel (img: Straumann Group)

The dental implant supplier Straumann increased revenue by 31.6 percent to 496 million Swiss francs in the third quarter of the year, further details of which can be found in a press release. For the full year, organic revenue growth in the high-thirties percentage range is being targeted, while profitability should at least be on a par with the level recorded in 2019. At the same time, the Basel-based firm is implementing an investment program to ensure it remains fit for the future. As such, it has announced that it will be investing a total of 18 million Swiss francs on the construction of a new technology and innovation center, which is expected to be operational by the first half of 2023.

Straumann will “host research and development, global supply chain, logistics and warehousing activities” at this new center. “In addition, the Swiss sales affiliate and commercial laboratory will be located at the site”, Straumann explains in the press release. As the newspaper “bz” writes in an article that includes comments from CEO Guillaume Daniellot, Straumann intends to create 240 new jobs at the technology and innovation center. The Arlesheim location is intended to emphasize the importance of the Basel Area for the company. In addition to the new jobs, Straumann will also bring together expert groups from the region at the new center. The company’s headquarters will remain at the site adjacent to Basel SBB railway station, according to an article by telebasel.

Furthermore, Straumann has made another investment, on this occasion acquiring a 39 percent stake in Mininavident, as the medtech firm from Liestal in the canton of Basel-Landschaft writes in a press release. The spin-off from the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) and University Hospital Basel has developed a navigation system for dental implants in the form of the DENACAM. Users receive real-time support in 3D to help accurately position the implant. In addition to the equity participation, the two firms have also agreed a partnership for the further development and distribution of the system, which will see Straumann become the worldwide exclusive distribution partner. Mininavident is very proud of this investment and cooperation with one of the world’s leading dental implant companies, CEO Michael Breitenstein comments in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.